Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Masat, Elisa ^a   Laforêt, Pascal ^a,b   De Antonio, Marie ^c   Corre, Guillaume ^d   Perniconi, Barbara ^b   Taouagh, Nadjib ^b   Mariampillai, Kuberaka ^b   Amelin, Damien ^a   Mauhin, Wladimir ^a   Hogrel, Jean Yves ^e   Caillaud, Catherine ^f   Ronzitti, Giuseppe ^d   Puzzo, Francesco ^d   Kuranda, Klaudia ^a   Colella, Pasqualina ^d   Mallone, Roberto ^c,g,h   Benveniste, Olivier ^a,b   Mingozzi, Federico ^a,d   Bassez, G ⁱ   Bedat Millet, A L ^j   Behin, A ^b   Eymard, B ^b   Leonard Louis, S ^b   Stojkovic, T ^b   Canal, A ^b   Decostre, V ^b   Bouhour, F ^k   Boyer, F ^l   Castaing, Y ^m   Chapon, F ⁿ   Cintas, P ^o   Durieu, I ^p   Echaniz Laguna, A ^q   Feasson, L ^r   Furby, A ^r   Hamroun, D ^s   Ferrer, X ^m   Sole G ^m   Froissart, R ^t   Piraud, M ^t   Germain, D ^u   Benistan, K ^u   Guffon Fouilhoux, N ^t   Journel, H ^v   Labauge, P ^w   Lacour, A ^x   Levy, A ^y   Magot, A ^z   Pereon Y ^z   Minot Myhie M C ^aa   Nadaj Pakleza, A ^ab   Nathier, C ^ab   Orlikowski, D ^u   Pellegrini, N ^ac   Petiot, P ^ad   Praline, J ^ae   Lofaso, F ^u   Prigent, H ^u   Dutry, A ^af   Renard, D ^af   Sacconi, S ^ag   Desnuelle, C ^ag   Salort Campana, E ^ah   Pouget, J ^ah   Tiffreau, V ^ai   Vincent, D ^aj   Zagnoli, F ^ak   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d GÉNÉTHON   (France)

^e Institute of Myology   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g INSTITUT COCHIN   (France)

^h Faculty of Medicine ^*  (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j HÔPITAL CHARLES NICOLLE   (France)

^k HÔPITAL NEUROLOGIQUE   (France)

^l REIMS UNIVERSITY HOSPITAL   (France)

^m BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁿ CAEN UNIVERSITY HOSPITAL   (France)

^o CHU RANGUEIL   (France)

^p CENTRE HOSPITALIER LYON SUD   (France)

^q HÔPITAL DE HAUTEPIERRE   (France)

^r HÔPITAL NORD   (France)

^s HÔPITAL ARNAUD DE VILLENEUVE   (France)

^t HOSPICES CIVILS DE LYON   (France)

^u RAYMOND POINCARÉ HOSPITAL   (France)

^v Centre Hospitalier Bretagne Atlantique   (France)

^w MONTPELLIER UNIVERSITY HOSPITAL   (France)

^x UNIV LILLE   (France)

^y Service Douleur et Soins Palliatifs   (France)

^z HÔTEL DIEU   (France)

^aa RENNES UNIVERSITY HOSPITAL   (France)

^ab ANGERS UNIVERSITY HOSPITAL   (France)

^ac Hôtel Dieu ^*  (France)

^ad CROIX ROUSSE HOSPITAL   (France)

^ae UNIVERSITY HOSPITAL OF TOURS   (France)

^af DEPARTMENT OF NEUROLOGY   (France)

^ag Centre de Référence des Maladies Neuromusculaires et SLA   (France)

^ah AIX MARSEILLE UNIVERSITY   (France)

^ai LILLE UNIVERSITY HOSPITAL   (France)

^aj Centre hospitalier de La Rochelle   (France)

^ak Military Teaching Hospital Clermont Tonnerre   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; ANTIBODY; GAA PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; IMMUNOGLOBULIN G; INTERLEUKIN 2;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; DENDRITIC CELL; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; ONSET AGE; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; AGED; ALPHA-GLUCOSIDASES; ANTIBODIES; CASE-CONTROL STUDIES; DENDRITIC CELLS; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2; MALE; MIDDLE AGED; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84994625437     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36182     Document Type: Article

References (65)

1. van der Ploeg, A. T. & Reuser, A. J. Pompe's disease. Lancet 372, 1342-1353, doi: 10.1016/S0140-6736(08)61555-X (2008).
2. Hirschhorn, R. a. R. AJJ. In The Metabolic and Molecular Basis of Inherited Disease (ed A. L. Beaudet, C. R. Scriver, W. S. Sly, D. Valle) 3389-3420 (McGraw-Hill, 2001).
3. Kroos, M., Hoogeveen-Westerveld, M., van der Ploeg, A. & Reuser, A. J. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C, 59-68, doi: 10.1002/ajmg.c.31318 (2012).
4. Kishnani, P. S. et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99, 26-33, doi: 10.1016/j.ymgme.2009.08.003 (2010).
5. Orlikowski, D. et al. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord 21, 477-482, doi: 10.1016/j.nmd.2011.04.001 (2011).
6. Teener, J. W. Late-onset Pompe's disease. Semin Neurol 32, 506-511, doi: 10.1055/s-0033-1334469 (2012).
7. Kishnani, P. S. et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99-109, doi: 10.1212/01.wnl.0000251268.41188.04 (2007).
8. Prater, S. N. et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14, 800-810, doi: 10.1038/gim.2012.44 (2012).
9. van der Ploeg, A. T. et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 107, 456-461, doi: 10.1016/j.ymgme.2012.09.015 (2012).
10. van der Ploeg, A. T. et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362, 1396-1406, doi: 10.1056/NEJMoa0909859 (2010).
11. Schoser, B. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol, doi: 10.1007/s00415-016-8219-8 (2016).
12. Mendelsohn, N. J., Messinger, Y. H., Rosenberg, A. S. & Kishnani, P. S. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 360, 194-195, doi: 10.1056/NEJMc0806809 (2009).
13. Banugaria, S. G. et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab 105, 677-680, doi: 10.1016/j.ymgme.2012.01.019 (2012).
14. Nicolino, M. et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11, 210-219, doi: 10.1097/GIM.0b013e31819d0996 (2009).
15. de Vries, J. M. et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101, 338-345, doi: 10.1016/j.ymgme.2010.08.009 (2010).
16. El-Gharbawy, A. H. et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab 104, 118-122, doi: 10.1016/j.ymgme.2011.07.004 (2011).
17. Linthorst, G. E., Hollak, C. E., Donker-Koopman, W. E., Strijland, A. & Aerts, J. M. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66, 1589-1595, doi: 10.1111/j.1523-1755.2004.00924.x (2004).
18. Germain, D. P., Kaneski, C. R. & Brady, R. O. Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase. Mutat Res 483, 89-94 (2001).
19. Banati, M., Hosszu, Z., Trauninger, A., Szereday, L. & Illes, Z. Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease. Muscle Nerve 44, 720-726, doi: 10.1002/mus.22136 (2011).
20. Nayak, S. et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One 9, e98336, doi: 10.1371/journal.pone.0098336 (2014).
21. Nayak, S. et al. Mapping the T helper cell response to acid alpha-glucosidase in Pompe mice. Mol Genet Metab 106, 189-195, doi: 10.1016/j.ymgme.2012.03.009 (2012).
22. Sun, B. et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 18, 353-360, doi: 10.1038/mt.2009.195 (2010).
23. Whelan, S. F. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 121, 1039-1048, doi: 10.1182/blood-2012-07-444877 (2013).
24. van de Veen, W. et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 131, 1204-1212, doi: 10.1016/j.jaci.2013.01.014 (2013).
25. Meiler, F., Klunker, S., Zimmermann, M., Akdis, C. A. & Akdis, M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 63, 1455-1463, doi: 10.1111/j.1398-9995.2008.01774.x (2008).
26. Martinuzzi, E. et al. acDCs enhance human antigen-specific T-cell responses. Blood 118, 2128-2137, doi: 10.1182/ blood-2010-12-326231 (2011).
27. Hu, G., Guo, D., Key, N. S. & Conti-Fine, B. M. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 97, 788-794 (2007).
28. Knoechel, B. et al. Functional and molecular comparison of anergic and regulatory T lymphocytes. J Immunol 176, 6473-6483 (2006).
29. Moran, E. M. & Mastaglia, F. L. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 178, 405-415, doi: 10.1111/cei.12445 (2014).
30. Palermo, A. T. et al. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients. Mol Genet Metab 106, 287-300, doi: 10.1016/j.ymgme.2012.05.004 (2012).
31. Prendergast, C. T., Sanin, D. E. & Mountford, A. P. CD4 T cell hypo-responsiveness induced by schistosome larvae is not dependent upon eosinophils but may involve connective tissue mast cells. Parasite Immunol, doi: 10.1111/pim.12300 (2015).
32. Blair, P. A. et al. CD19(+ )CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32, 129-140, doi: 10.1016/j.immuni.2009.11.009 (2010).
33. Kishnani, P. S. et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab, doi: 10.1016/j.ymgme.2015.11.001 (2015).
34. Keiserman, M. et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol 10, 1049-1057, doi: 10.1586/1744666X.2014.926219 (2014).
35. Fakharzadeh, S. S. & Kazazian, H. H., Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26, 167-171, doi: 10.1055/s-2000-9819 (2000).
36. Shankar, G., Pendley, C. & Stein, K. E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25, 555-561, doi: 10.1038/nbt1303 (2007).
37. Bartelds, G. M. et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum 60, 2541-2542, doi: 10.1002/art.24709 (2009).
38. Flanigan, K. M. et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24, 797-806, doi: 10.1089/hum.2013.092 (2013).
39. Mendell, J. R. et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363, 1429-1437, doi: 10.1056/ NEJMoa1000228 (2010).
40. Disease, A. W. G. o. M. o. P. et al. Pompe disease diagnosis and management guideline. Genet Med 8, 267-288, doi: 10.109701. gim.0000218152.87434.f3 (2006).
41. Patel, T. T. et al. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 106, 301-309, doi: 10.1016/j.ymgme.2012.04.027 (2012).
42. Wroblewska, A., Reipert, B. M., Pratt, K. P. & Voorberg, J. Dangerous liaisons: how the immune system deals with factor VIII. J Thromb Haemost 11, 47-55, doi: 10.1111/jth.12065 (2013).
43. Nascimbeni, A. C., Fanin, M., Tasca, E., Angelini, C. & Sandri, M. Impaired autophagy affects acid alpha-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II. Neuropathol Appl Neurobiol 41, 672-675, doi: 10.1111/nan.12214 (2015).
44. Lucia, A. et al. McArdle disease: another systemic low-inflammation disorder? Neurosci Lett 431, 106-111, doi: 10.1016/j. neulet.2007.11.028 (2008).
45. Allen, M. J., Myer, B. J., Khokher, A. M., Rushton, N. & Cox, T. M. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 90, 19-25 (1997).
46. Messinger, Y. H. et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14, 135-142, doi: 10.1038/gim.2011.4 (2012).
47. Banugaria, S. G. et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15, 123-131, doi: 10.1038/gim.2012.110 (2013).
48. Montalvao, S. A. et al. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with hightitre inhibitor in haemophilia A patients. Haemophilia 21, 686-692, doi: 10.1111/hae.12646 (2015).
49. Moorehead, P. C. et al. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor. J Pediatr Hematol Oncol 37, e220-e222, doi: 10.1097/MPH.0000000000000287 (2015).
50. Akdis, C. A. & Akdis, M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest 124, 4678-4680, doi: 10.1172/JCI78891 (2014).
51. Renand, A. et al. Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization. J Allergy Clin Immunol 136, 1627-1635, e1613, doi: 10.1016/j.jaci.2015.07.031 (2015).
52. Santos, A. F. et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 135, 1249-1256, doi: 10.1016/j.jaci.2015.01.012 (2015).
53. Aalberse, R. C., van der Gaag, R. & van Leeuwen, J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130, 722-726 (1983).
54. Dazzi, F. et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 93, 688-693 (1996).
55. Dickson, P. et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 118, 2868-2876, doi: 10.1172/JCI34676 (2008).
56. Kakavanos, R., Turner, C. T., Hopwood, J. J., Kakkis, E. D. & Brooks, D. A. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 361, 1608-1613, doi: 10.1016/S0140-6736(03)13311-9 (2003).
57. Han, S. O. et al. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther 26, 26-35, doi: 10.1089/hum.2014.115 (2015).
58. Oldenburg, J., Schwaab, R. & Brackmann, H. H. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 77 Suppl 1, 49-54, doi: 56717 (1999).
59. Singh, N. J. & Schwartz, R. H. The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells. J Exp Med 198, 1107-1117, doi: 10.1084/jem.20030913 (2003).
60. Kazi, Z. B. et al. Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight 1, doi: 10.1172/jci.insight.86821 (2016).
61. Lipinski, S. E., Lipinski, M. J., Burnette, A., Platts-Mills, T. A. & Wilson, W. G. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab 98, 319-321, doi: 10.1016/j.ymgme.2009.07.001 (2009).
62. Park, J. S., Kim, H. G., Shin, J. H., Choi, Y. C. & Kim, D. S. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of weeks follow-up. Neurol Sci 36, 599-605, doi: 10.1007/s10072-014-2000-5 (2015).
63. Galjaard, H., Mekes, M., Josselin de Jong, J. D. & Niermeijer, M. F. A method for rapid prenatal diagnosis of glycogenosis II (Pompe's disease). Clin Chim Acta 49, 361-375 (1973).
64. Mingozzi, F. et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsidspecific T cells. Blood 114, 2077-2086, doi: 10.1182/blood-2008-07-167510 (2009).
65. Verbeke, G. & Molenberghs, G. Linear Mixed Models for Longitudinal Data. Springer, New York, NY, USA (2000).